UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~October 284, 2016

Cynapsus Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Canada	001-37426	98-1226819
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

828 Richmond Street West,

Toronto, Ontario, Canada

(Address of principal executive offices)

M6J 1C9

(Zip Code)

Registrant’s telephone number, including area code: 416-703-2449

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 73.0102 ~~Regulation~~Unregistered FDSales ~~Disclosure~~of Equity Securities.

On From September 2820, 2016 to October 11, 2016, Cynapsus Therapeutics Inc. (the “Company”) issued aan ~~press~~aggregate ~~release~~of ~~announcing~~249,254 common ~~that~~shares ~~Institutional~~pursuant ~~Shareholder~~to ~~Services~~the ~~(ISS)~~exercise ~~has~~of ~~recommended~~warrants, for aggregate cash consideration of approximately Cdn$3,221,029. Such common ~~that~~shares were issued by the Company’s ~~shareholders~~in the United States and ~~warrantholders~~to ~~vote~~“U.S. ~~FOR~~persons” ~~the~~(as ~~special~~both ~~resolution~~such toterms ~~approve~~are defined in Regulation S (“Regulation S”) under the ~~previously~~United ~~announced~~States ~~plan~~ Securities Act of ~~arrangement~~1933, ~~with~~as ~~Sunovion~~amended ~~CNS~~(the ~~Development~~“Securities ~~Canada~~Act”)), in ~~ULC.~~reliance ~~The~~upon ~~full~~Rule ~~text~~506(b) of Regulation D under the ~~press~~Securities ~~release~~Act is(“Regulation ~~being~~D”), ~~furnished~~solely to “accredited investors,” as ~~Exhibit~~such ~~99.1 to~~term ~~this~~is ~~Form~~defined ~~8-K,~~in ~~and~~Rule ~~shall~~501(a) ~~not~~of beRegulation ~~deemed~~D. ~~filed~~Such ~~under~~common shares were issued outside the United States to ~~Securities~~non-U.S. ~~Exchange~~persons ~~Act~~in ofreliance ~~1934,~~upon asRegulation ~~amended~~S.

~~Item 9.01 Financial~~SIGNATURES ~~Statements and Exhibits.~~

d)Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The following exhibit is furnished herewith:

	CYNAPSUS THERAPEUTICS INC.


Date: October 11, 2016	By:	/s/ Andrew Williams
	Name:	Andrew Williams
	Title:	Chief Operating Officer and Chief Financial Officer

Exhibit No.		Description
99.1		Press release dated September 28, 2016.

SIGNATURES

Pursuant to the requirements of the United States Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CYNAPSUS THERAPEUTICS INC.
Date: September 29, 2016		By: /s/ Andrew Williams
		Name: Andrew Williams
		Title: Chief Operating Officer and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release dated September 28, 2016.

Filing Compare · SUNOVION CNS DEVELOPMENT CANADA ULC